Study: NCT02246712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single oral dose of 100 mg racemic tramadol
Description: Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of 100 mg racemic tramadol
Description: Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of 100 mg racemic tramadol
Description: Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CYP2D6 phenotype
Description: Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP2D6 phenotype
Description: Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP2D6 phenotype
Description: Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CYP3A phenotype
Description: A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP3A phenotype
Description: A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP3A phenotype
Description: A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2B6 genotype
Description: The single nucleotide polymorphism 516G\>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2B6 genotype
Description: The single nucleotide polymorphism 516G\>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2B6 genotype
Description: The single nucleotide polymorphism 516G\>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).